Ukraine

Reimbursed Care Access

As of February 20, 2026, Ukraine permits routine medical use of ketamine as an anaesthetic and limited off-label therapeutic ketamine administration in at least one hospital; other classic psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, ayahuasca, mescaline, 2C‑X) are controlled and are not authorized for routine medical care outside of tightly restricted research or are explicitly prohibited. The Ministry of Health and the State Drugs and Medications Control Service remain the key national authorities shaping policy; an interagency policy discussion and advocacy for psychedelic-assisted therapy (PAT) frameworks has been publicly reported but has not converted into broad regulatory approvals or public reimbursement for psychedelic medicines beyond established pharmaceuticals and off‑label ketamine practice. [https://cms-lawnow.com/en/ealerts/2023/10/ukrainian-health-ministry-supports-use-of-psychedelic-assisted-therapy|CMS Law-Now] [https://en.wikipedia.org/wiki/State_Service_for_Medications_and_Drugs_Control|State Drugs and Medications Control Service]